LamdaGen and Arisan Therapeutics Receive a $2 Million NIH SBIR Phase II Grant to Develop a Dual Rapid Point-of-Care Test for Acute Dengue and Zika Viral Infections

MENLO PARK & SAN DIEGO, Calif., June 26, 2019 /PRNewswire/ -- LamdaGen Corporation and Arisan Therapeutics announced today they will share a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH), to develop a high-sensitivity point-of-care (POC) dual diagnostic to detect both acute dengue and Zika viral infections in a single rapid test on LamdaGen's L'AuRa digital diagnostic platform.

The L'AuRa platform enables robust diagnostic testing that is simple, compact and cost-effective with no moving parts. L'AuRa technology can be integrated into designs ranging from miniaturized handhelds to small desktops to lab-based throughput systems, each providing powerful on-the-spot performance of high-sensitivity, rapid and quantitative diagnostic assays.

Global incidence of dengue has grown dramatically in recent decades with half of the world's population now at risk. In fact, incidence of both dengue and Zika are escalating and prone to unpredictable outbreaks due to climate shifts and proliferation of carriers such as mosquitoes and ticks. Currently, an estimated 390 million dengue infections occur annually. Of these, approximately 500,000 cases develop into life-threatening dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), severe forms of the disease which result in over 25,000 deaths globally each year.

"Early diagnosis of patients with dengue, in particular, is critical for timely clinical intervention and disease control," commented Randolph Storer, CEO of LamdaGen. "Dengue and Zika are closely related and currently there is no FDA-approved multiplex POC test that can differentiate between the two during the acute phases of infection. Our collaborators at Arisan have identified highly specific antibodies for each test, which we are integrating into the development on the L'AuRa platform."

In addition to enabling differentiation between the two viruses, this highly sensitive and quantitative POC assay will have the potential to act as a prognostic for identifying patients at risk of developing severe forms of dengue including DHF and DSS based on concentration of viral antigen found in blood. Early identification of at-risk patients may help reduce mortality and morbidity by enabling immediate monitoring and medical care.

Speaking of the importance of this NIH grant, Ken McCormack, president of Arisan, added, "We are very appreciative of NIH's support and excited to move forward in our collaboration with LamdaGen to develop these potentially life-saving solutions."

About LamdaGen Corporation - Based in Menlo Park, California, LamdaGen is a developer of nano-based plasmonic biosensors and robust diagnostic systems. The company is increasing access to healthcare with its L'AuRa diagnostic platform, a game-changing technology. L'AuRa is an immuno-based platform that combines the high sensitivity and precision of ELISA with the simplicity and speed of lateral flow to enable quantitative and rapid detection of diseases, pathogens and contaminants. LamdaGen licenses its L'AuRa technology to companies in the human diagnostic, companion animal and food safety industries. www.LamdaGen.com

About Arisan Therapeutics Inc. - A privately held life science company based in San Diego, California, Arisan was founded to develop therapeutics for neglected and emerging viral diseases, focusing on infectious diseases with the potential for significant impact on public health and those classified as priority biodefense-related pathogens. The company's mission is to identify unmet medical needs and provide appropriate solutions through development, collaboration and partnerships to benefit patients with life-threatening infectious diseases. www.arisanthera.com 

Disclaimer: Research supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI127055. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media Contact: 
Alice Huang
[email protected]

Related Images

lamdagen-corporation.jpg
LamdaGen Corporation
Developer of nano-based plasmonic biosensors and robust diagnostic systems to enable quantitative and rapid detection of diseases, pathogens and contaminants. www.LamdaGen.com

Related Links

L'AuRa Digital Platform for POC

About LamdaGen

SOURCE LamdaGen Corporation

Related Links

http://www.LamdaGen.com